Sensorion
Sensorion [ALSEN] is a biopharmaceutical company, formed in 2009, focused as a “pure player” on developing therapies for debilitating inner ear disorders. Sensorion’s mission is to offer innovative therapeutic solutions providing long-term improvements to people living with, or at risk of, inner ear disorders. Sensorion’s portfolio of solutions to unmet medical and social needs in inner ear disorders rests on three pillars – Restore, Treat, Prevent.
Sector
Biopharmaceuticals
Strategy
Crossover
Status
Live
Website
www.sensorion.com
Related News
Sensorion announces positive recommendation from the Data Safety Monitoring Board (DSMB) regarding the continuation of NOTOXIS, its Phase 2a clinical trial of SENS-401 in cisplatin-induced ototoxicity
Sensorion announces new positive secondary efficacy endpoints data From SENS-401 Phase 2a clinical trial for the preservation of residual hearing loss
Sensorion announces the appointment of Laurene Danon as Chief Financial Officer
Sensorion announces a €15 Million financing, extending cash runway until the end of 2025
Sensorion announces it has met primary endpoint for SENS-401 Phase 2a Clinical Study for residual hearing preservation
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.